Open Access
Tableau I.
Modulateurs du complément en cours d’essai dans la COVID-19.
| Numéro | Molécule | Cible | Compagnie | Essai clinique/Phase (ClinicalTrials.gov) |
|---|---|---|---|---|
| Anticorps monoclonaux inhibiteurs | ||||
| 1 | Éculizumab | C5 | Alexion | NCT02574403/IV, NCT04288713, NCT04346797, NCT04355494 |
| 2 | Ravulizumab | C5 | Alexion | NCT03131219, NCT02949128/III, NCT04570397, NCT04390464, NCT04369469 |
| 3 | Narsoplimab (OMS721) | MASP-2 | Omeros | NCT02682407, NCT03205995/II |
| 4 | AMY101 | C3 | Amyndas | NCT03316521/I, NCT04395456 |
| 5 | BDB-001 | C5a | Staidon Biopharmaceutical | NCT04449588/II |
| 6 | Sutimlimab | C1s | Sanofi/Bioverativ | NCT03347422, NCT03347396/III |
| 7 | Lampalizumab | Facteur D | Genentech/Roche | NCT02247531, NCT02247479/III |
| 8 | Avdoralimab (IPH5401) | C5aR1 | Innate Pharma | NCT03665129/I, NCT04371367 |
| 9 | Tésidolumab (LFG-316) | C5 | Novartis | NCT02878616 /I |
| 10 | Pozélimab/REGN3918 | C5 | Regeneron | NCT03115996/I |
| 11 | SKY59/RO7112689 | C5 | Hoffmann-La Roche | NCT03157635/I-II |
| 12 | ABP959 | C5 | Amgen | NCT03818607/III |
| 13 | SB12 | C5 | Samsung Bioepis | NCT03722329/I |
| 14 | Vilobélimab (IFX-1) | C5a | InfaRx | NCT03712345/III, NCT04333420 |
| Peptides ou protéines inhibiteurs (Peptide/protein-based inhibitors) | ||||
| 15 | Contestat alfa | C1 estérase | Pharming Group | NCT04414631/II, NCT04530136 |
| 16 | CINRYZE | C1 estérase | ShirePharmaceuticals Ltd | NCT02052141/Approved |
| 17 | APL-2 | C3 | Apellis | NCT03453619/II |
| 18 | APL-9 | C3 | Apellis | NCT04402060/II |
| 19 | Coversin/rVA576 | C5 | Akari Therapeutics | NCT03829449/III |
| 20 | Zilucoplan | C5 | Ra Pharma | NCT04115293/III, NCT04382755 |
| 21 | PMX-53 | C5a/C5aR | ||
| 22 | C1-INH/Berinert | C1r/C1s | Cedars-Sinai Medical Center | NCT02134314/I |
| 23 | Mirococept | C3 et C5 convertases | ||
| 24 | TP10/ CDX1135 | C3 et C5 convertases | Avant Immunotherapeutics | NCT00082121/II |
| Oligonucléotides inhibiteurs (Oligonucleotide-based inhibitors) | ||||
| 25 | Cemdisiran or ALN-CC5 | C5 | Alnylam Pharmaceuticals | NCT03841448/II |
| Petites molécules inhibitrices (Small molecule-based inhibitors) | ||||
| 26 | CCX168 | C5aR1 | ChemoCentryx | NCT02384317/II |
| 27 | ACH0144471 | Facteur D | Achillion | NCT03459443, NCT03124368/II |
| 28 | ACH145951 | Facteur D | [24] | |
| 29 | LPN023 | Facteur B | Novartis | NCT03373461/II |
| 30 | 1-(3,4-Diméthoxyphényl)- 3-(1-phényléthyl) urée | C5 convertase | [57] | |
| Inhibiteurs issus de plantes (Plant metabolite-based inhibitors) | ||||
| 31 | Rosmarinic acid | C3 convertase | [58] | |
| 32 | Boswellic acid | C3 convertase | [59, 60] | |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.